Spots Global Cancer Trial Database for yttrium y 90 basiliximab
Every month we try and update this database with for yttrium y 90 basiliximab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma | NCT02342782 | Mature T-Cell a... Recurrent Matur... Refractory Matu... Recurrent Cutan... Refractory Cuta... | Yttrium Y 90 Ba... Carmustine Etoposide Cytarabine Melphalan Autologous Hema... Laboratory Biom... Pharmacological... | 18 Years - | City of Hope Medical Center | |
| 90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome | NCT05139004 | Acute Lymphobla... Acute Myeloid L... Myelodysplastic... Secondary Acute... | Allogeneic Hema... Basiliximab Fludarabine Pho... Indium In 111-D... Melphalan Palifermin Total Lymphoid ... Total Marrow Ir... Yttrium Y 90 Ba... | 60 Years - | City of Hope Medical Center | |
| 90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome | NCT05139004 | Acute Lymphobla... Acute Myeloid L... Myelodysplastic... Secondary Acute... | Allogeneic Hema... Basiliximab Fludarabine Pho... Indium In 111-D... Melphalan Palifermin Total Lymphoid ... Total Marrow Ir... Yttrium Y 90 Ba... | 60 Years - | City of Hope Medical Center | |
| Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma | NCT04871607 | Recurrent Hodgk... Refractory Hodg... | Basiliximab Carmustine Cytarabine Etoposide Genetically Eng... Recombinant Gra... Yttrium Y 90 Ba... | 18 Years - | City of Hope Medical Center | |
| 90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome | NCT05139004 | Acute Lymphobla... Acute Myeloid L... Myelodysplastic... Secondary Acute... | Allogeneic Hema... Basiliximab Fludarabine Pho... Indium In 111-D... Melphalan Palifermin Total Lymphoid ... Total Marrow Ir... Yttrium Y 90 Ba... | 60 Years - | City of Hope Medical Center | |
| 90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome | NCT05139004 | Acute Lymphobla... Acute Myeloid L... Myelodysplastic... Secondary Acute... | Allogeneic Hema... Basiliximab Fludarabine Pho... Indium In 111-D... Melphalan Palifermin Total Lymphoid ... Total Marrow Ir... Yttrium Y 90 Ba... | 60 Years - | City of Hope Medical Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
